23andMe teams up with Genentech on Parkinson's genomics
This article was originally published in Clinica
Executive Summary
Personal genetics firm 23andMe is teaming up with pharma company Genentech, a Roche subsidiary, to analyze the genomes of Parkinson's disease patients in the hope of finding new drug targets.